256 related articles for article (PubMed ID: 25240592)
1. Inhibition of prolyl oligopeptidase increases the survival of alpha-synuclein overexpressing cells after rotenone exposure by reducing alpha-synuclein oligomers.
Dokleja L; Hannula MJ; Myöhänen TT
Neurosci Lett; 2014 Nov; 583():37-42. PubMed ID: 25240592
[TBL] [Abstract][Full Text] [Related]
2. Prolyl oligopeptidase inhibition attenuates the toxicity of a proteasomal inhibitor, lactacystin, in the alpha-synuclein overexpressing cell culture.
Myöhänen TT; Norrbacka S; Savolainen MH
Neurosci Lett; 2017 Jan; 636():83-89. PubMed ID: 27818354
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of Prolyl Oligopeptidase Restores Spontaneous Motor Behavior in the α-Synuclein Virus Vector-Based Parkinson's Disease Mouse Model by Decreasing α-Synuclein Oligomeric Species in Mouse Brain.
Svarcbahs R; Julku UH; Myöhänen TT
J Neurosci; 2016 Dec; 36(49):12485-12497. PubMed ID: 27927963
[TBL] [Abstract][Full Text] [Related]
4. The beneficial effect of a prolyl oligopeptidase inhibitor, KYP-2047, on alpha-synuclein clearance and autophagy in A30P transgenic mouse.
Savolainen MH; Richie CT; Harvey BK; Männistö PT; Maguire-Zeiss KA; Myöhänen TT
Neurobiol Dis; 2014 Aug; 68():1-15. PubMed ID: 24746855
[TBL] [Abstract][Full Text] [Related]
5. A prolyl oligopeptidase inhibitor, KYP-2047, reduces α-synuclein protein levels and aggregates in cellular and animal models of Parkinson's disease.
Myöhänen TT; Hannula MJ; Van Elzen R; Gerard M; Van Der Veken P; García-Horsman JA; Baekelandt V; Männistö PT; Lambeir AM
Br J Pharmacol; 2012 Jun; 166(3):1097-113. PubMed ID: 22233220
[TBL] [Abstract][Full Text] [Related]
6. Prolyl oligopeptidase enhances α-synuclein dimerization via direct protein-protein interaction.
Savolainen MH; Yan X; Myöhänen TT; Huttunen HJ
J Biol Chem; 2015 Feb; 290(8):5117-5126. PubMed ID: 25555914
[TBL] [Abstract][Full Text] [Related]
7. Prolyl oligopeptidase inhibition by KYP-2407 increases alpha-synuclein fibril degradation in neuron-like cells.
Rostami J; Jäntti M; Cui H; Rinne MK; Kukkonen JP; Falk A; Erlandsson A; Myöhänen T
Biomed Pharmacother; 2020 Nov; 131():110788. PubMed ID: 33152946
[TBL] [Abstract][Full Text] [Related]
8. The effect of prolyl oligopeptidase inhibitors on alpha-synuclein aggregation and autophagy cannot be predicted by their inhibitory efficacy.
Kilpeläinen TP; Hellinen L; Vrijdag J; Yan X; Svarcbahs R; Vellonen KS; Lambeir AM; Huttunen H; Urtti A; Wallen EAA; Myöhänen TT
Biomed Pharmacother; 2020 Aug; 128():110253. PubMed ID: 32447211
[TBL] [Abstract][Full Text] [Related]
9. Proteasomal inhibition hypersensitizes differentiated neuroblastoma cells to oxidative damage.
Lev N; Melamed E; Offen D
Neurosci Lett; 2006 May; 399(1-2):27-32. PubMed ID: 16584840
[TBL] [Abstract][Full Text] [Related]
10. Neuroprotection of α-synuclein under acute and chronic rotenone and maneb treatment is abolished by its familial Parkinson's disease mutations A30P, A53T and E46K.
Choong CJ; Say YH
Neurotoxicology; 2011 Dec; 32(6):857-63. PubMed ID: 21658409
[TBL] [Abstract][Full Text] [Related]
11. Removal of prolyl oligopeptidase reduces alpha-synuclein toxicity in cells and in vivo.
Svarcbahs R; Julku UH; Norrbacka S; Myöhänen TT
Sci Rep; 2018 Jan; 8(1):1552. PubMed ID: 29367610
[TBL] [Abstract][Full Text] [Related]
12. Prolyl oligopeptidase inhibition reduces alpha-synuclein aggregation in a cellular model of multiple system atrophy.
Cui H; Kilpeläinen T; Zouzoula L; Auno S; Trontti K; Kurvonen S; Norrbacka S; Hovatta I; Jensen PH; Myöhänen TT
J Cell Mol Med; 2021 Oct; 25(20):9634-9646. PubMed ID: 34486218
[TBL] [Abstract][Full Text] [Related]
13. Linking alpha-synuclein phosphorylation to reactive oxygen species formation and mitochondrial dysfunction in SH-SY5Y cells.
Perfeito R; Lázaro DF; Outeiro TF; Rego AC
Mol Cell Neurosci; 2014 Sep; 62():51-9. PubMed ID: 25109238
[TBL] [Abstract][Full Text] [Related]
14. Prolyl oligopeptidase acts as a link between chaperone-mediated autophagy and macroautophagy.
Cui H; Norrbacka S; Myöhänen TT
Biochem Pharmacol; 2022 Mar; 197():114899. PubMed ID: 34968496
[TBL] [Abstract][Full Text] [Related]
15. Endoplasmic reticulum stress and mitochondrial cell death pathways mediate A53T mutant alpha-synuclein-induced toxicity.
Smith WW; Jiang H; Pei Z; Tanaka Y; Morita H; Sawa A; Dawson VL; Dawson TM; Ross CA
Hum Mol Genet; 2005 Dec; 14(24):3801-11. PubMed ID: 16239241
[TBL] [Abstract][Full Text] [Related]
16. Removal of proteinase K resistant αSyn species does not correlate with cell survival in a virus vector-based Parkinson's disease mouse model.
Eteläinen TS; Kilpeläinen TP; Ignatius A; Auno S; De Lorenzo F; Uhari-Väänänen JK; Julku UH; Myöhänen TT
Neuropharmacology; 2022 Nov; 218():109213. PubMed ID: 35964686
[TBL] [Abstract][Full Text] [Related]
17. Rotenone down-regulates HSPA8/hsc70 chaperone protein in vitro: A new possible toxic mechanism contributing to Parkinson's disease.
Sala G; Marinig D; Riva C; Arosio A; Stefanoni G; Brighina L; Formenti M; Alberghina L; Colangelo AM; Ferrarese C
Neurotoxicology; 2016 May; 54():161-169. PubMed ID: 27133439
[TBL] [Abstract][Full Text] [Related]
18. Posttranslational modification and mutation of histidine 50 trigger alpha synuclein aggregation and toxicity.
Xiang W; Menges S; Schlachetzki JC; Meixner H; Hoffmann AC; Schlötzer-Schrehardt U; Becker CM; Winkler J; Klucken J
Mol Neurodegener; 2015 Mar; 10():8. PubMed ID: 25886189
[TBL] [Abstract][Full Text] [Related]
19. Prolyl oligopeptidase stimulates the aggregation of alpha-synuclein.
Brandt I; Gérard M; Sergeant K; Devreese B; Baekelandt V; Augustyns K; Scharpé S; Engelborghs Y; Lambeir AM
Peptides; 2008 Sep; 29(9):1472-8. PubMed ID: 18571285
[TBL] [Abstract][Full Text] [Related]
20. Alpha synuclein dimers and oligomers are increased in overexpressing conditions in vitro and in vivo.
Marmolino D; Foerch P; Atienzar FA; Staelens L; Michel A; Scheller D
Mol Cell Neurosci; 2016 Mar; 71():92-101. PubMed ID: 26711807
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
